VIP and Parkinson disease: Vasoactive intestinal peptide (VIP) and VIP receptor-2 (VIPR2) agonists also increase Treg frequency and function, and these agents and their induced Tregs are anti-inflammatory and neuroprotective in animal models of PD [99], 100].